Baillie Gifford & Co. Raises Holdings in Insulet Co. (NASDAQ:PODD)

Baillie Gifford & Co. lifted its stake in shares of Insulet Co. (NASDAQ:PODD - Free Report) by 3.5% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 2,355,683 shares of the medical instruments supplier's stock after acquiring an additional 79,982 shares during the quarter. Baillie Gifford & Co. owned approximately 3.36% of Insulet worth $614,998,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Mizuho Securities USA LLC raised its holdings in Insulet by 5,928.1% during the 3rd quarter. Mizuho Securities USA LLC now owns 325,821 shares of the medical instruments supplier's stock valued at $75,835,000 after buying an additional 320,416 shares during the period. Charles Schwab Investment Management Inc. boosted its holdings in Insulet by 43.8% in the third quarter. Charles Schwab Investment Management Inc. now owns 636,265 shares of the medical instruments supplier's stock worth $148,091,000 after acquiring an additional 193,839 shares in the last quarter. Westfield Capital Management Co. LP boosted its holdings in Insulet by 27.6% in the third quarter. Westfield Capital Management Co. LP now owns 754,872 shares of the medical instruments supplier's stock worth $175,697,000 after acquiring an additional 163,388 shares in the last quarter. Caisse DE Depot ET Placement DU Quebec purchased a new position in shares of Insulet in the third quarter worth about $16,342,000. Finally, Jennison Associates LLC raised its stake in shares of Insulet by 113.8% in the third quarter. Jennison Associates LLC now owns 129,967 shares of the medical instruments supplier's stock worth $30,250,000 after purchasing an additional 69,180 shares during the last quarter.

Insider Transactions at Insulet

In other Insulet news, CAO Lauren Budden sold 915 shares of Insulet stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $275.62, for a total value of $252,192.30. Following the sale, the chief accounting officer now owns 5,733 shares in the company, valued at $1,580,129.46. The trade was a 13.76 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Eric Benjamin sold 12,394 shares of Insulet stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $280.00, for a total value of $3,470,320.00. Following the completion of the sale, the executive vice president now owns 11,383 shares in the company, valued at $3,187,240. This represents a 52.13 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 0.47% of the company's stock.

Insulet Price Performance

Shares of Insulet stock traded up $4.61 on Thursday, reaching $288.29. The company's stock had a trading volume of 850,183 shares, compared to its average volume of 548,768. The company has a market capitalization of $20.22 billion, a P/E ratio of 49.36, a PEG ratio of 3.52 and a beta of 1.23. Insulet Co. has a 52-week low of $160.19 and a 52-week high of $289.46. The stock has a 50-day moving average price of $272.37 and a 200-day moving average price of $246.18. The company has a quick ratio of 2.80, a current ratio of 3.68 and a debt-to-equity ratio of 1.21.

Insulet (NASDAQ:PODD - Get Free Report) last issued its quarterly earnings results on Thursday, February 20th. The medical instruments supplier reported $1.15 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.00 by $0.15. Insulet had a return on equity of 27.98% and a net margin of 21.22%. Analysts expect that Insulet Co. will post 3.22 EPS for the current year.

Analyst Ratings Changes

Several research analysts have recently issued reports on PODD shares. Morgan Stanley raised their price objective on Insulet from $234.00 to $317.00 and gave the stock an "overweight" rating in a research note on Monday, November 11th. Barclays raised their price objective on Insulet from $220.00 to $234.00 and gave the stock an "equal weight" rating in a research note on Monday, November 11th. BTIG Research raised their price objective on Insulet from $260.00 to $270.00 and gave the stock a "buy" rating in a research note on Friday, November 8th. Sanford C. Bernstein started coverage on Insulet in a research note on Wednesday, November 6th. They issued an "outperform" rating and a $300.00 price objective for the company. Finally, Canaccord Genuity Group raised their price objective on Insulet from $269.00 to $304.00 and gave the stock a "buy" rating in a research note on Monday, December 9th. Two analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company's stock. According to MarketBeat, Insulet presently has an average rating of "Moderate Buy" and a consensus price target of $277.13.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.